| Identification | Back Directory | [Name]
PROSTAGLANDIN J2 | [CAS]
60203-57-8 | [Synonyms]
PGJ2
Aids058772
Aids-058772
PROSTAGLANDIN J2
PGJ2 (Prostaglandin J2)
Prostaglandin J2 (PGJ2)
9-deoxy-delta-9-prostaglandind2
Prostaglandin J2 Lipid Maps MS Standard
PROSTAGLANDIN J2, 5MG/ML IN METHYL ACETA
11-OXO-15S-HYDROXY-PROSTA-5Z,9,13E-TRIEN-1-OIC ACID
(5Z,13E,15S)-15-HYDROXY-11-OXOPROSTA-5,9,13-TRIEN-1-OIC ACID
(5Z,13E,15S)-15-Hydroxy-11-oxoprosta-5,9,13-triene-1-oic acid
Prosta-5,9,13-trien-1-oic acid, 15-hydroxy-11-oxo-, (5Z,13E,15S)-
(Z)-7-[(1S,5R)-5-[(E,3S)-3-hydroxyoct-1-enyl]-4-oxo-1-cyclopent-2-enyl]hept-5-enoic acid | [EINECS(EC#)]
201-185-2 | [Molecular Formula]
C20H30O4 | [MDL Number]
MFCD00065804 | [MOL File]
60203-57-8.mol | [Molecular Weight]
334.45 |
| Chemical Properties | Back Directory | [Boiling point ]
521.7±50.0 °C(Predicted) | [density ]
1.103±0.06 g/cm3(Predicted) | [storage temp. ]
−20°C | [solubility ]
DMF: >100 mg/ml (from PGD2); DMSO: >50 mg/ml (from PGD2); Ethanol: >75 mg/ml (from PGD2); PBS pH 7.2: >2.7 mg/ml (from 15-deoxy-.DEL | [form ]
Liquid | [pka]
4.75±0.10(Predicted) | [color ]
Colorless to light yellow |
| Hazard Information | Back Directory | [Description]
Prostaglandin J2 (PGJ2) is formed from PGD2 by the elimination of the C-9 hydroxyl group, a process which is accelerated by the presence of albumin. PGJ2 inhibits platelet aggregation with an IC50 of about 5-10 nM. PGJ2 has antimitotic and antiproliferative effects on a variety of cultured normal cells and tumor cell lines. However, this activity has been attributed to further metabolites of PGJ2 and not the parent compound itself. | [Uses]
PGJ2 (Prostaglandin J2) is a Prostaglandin D2 metabolite that has shown potent anti-neoplastic and antiviral activity. | [Definition]
ChEBI: A member of the class of prostaglandins J that consists of prosta-5,9,13-trien-1-oic acid substituted by an oxo group at position 11 and a hydroxy group at position 15 (the 5Z,13E,15S stereoisomer). | [in vivo]
Prostaglandin J2 (PGJ2; 33.4 μg/injection; unilateral injection to the SNpc; once per week for 2 or 4 weeks) induces progressive PD-like pathology and exhibites microglia and astrocyte activation and motor deficits in the rats[4].
| Animal Model: | Sixteen-week-old Sprague Dawley male rats[4] | | Dosage: | 33.4 μg/injection | | Administration: | Unilateral (right side) injections to the SNpc; once per week for 2 or 4 weeks | | Result: | Induced progressive dopaminergic neuronal loss in the rat substantia nigra pars compacta (SNpc).
Developed parkinsonian-like motor deficits in a progressive manner.
|
| [IC 50]
hDP: 0.9 nM (Ki); hCRTH2: 6.6 nM (Ki); hEP1: 15.678 μM (Ki); hEP2: 989 nM (Ki); hEP3: 319 nM (Ki); hEP4: 1065 nM (Ki); hFP: 553 nM (Ki); hIP: >25 μM (Ki); hTP: 6426 nM (Ki); Human Endogenous Metabolite | [References]
[1] D. HAMISH WRIGHT. Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist[J]. British Journal of Pharmacology, 2009, 123 7: 1317-1324. DOI: 10.1038/sj.bjp.0701708
[2] NICOLE SAWYER. Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2[J]. British Journal of Pharmacology, 2009, 137 8: 1163-1172. DOI: 10.1038/sj.bjp.0704973
[3] TENEKA JEAN-LOUIS Maria E F P Patricia Rockwell. Prostaglandin J2 promotes O-GlcNAcylation raising APP processing by α- and β-secretases: relevance to Alzheimer’s disease[J]. Neurobiology of Aging, 2018, 62: Pages 130-145. DOI: 10.1016/j.neurobiolaging.2017.10.009
[4] MARIA E. FIGUEIREDO-PEREIRA John B Chuhyon Corwin. Prostaglandin J2: a potential target for halting inflammation-induced neurodegeneration?[J]. Annals of the New York Academy of Sciences, 2016, 1363 1: 125-137. DOI: 10.1111/nyas.12987
[5] CHUHYON CORWIN. Prostaglandin D2/J2 signaling pathway in a rat model of neuroinflammation displaying progressive parkinsonian-like pathology: potential novel therapeutic targets.[J]. Journal of Neuroinflammation, 2018: 272. DOI: 10.1186/s12974-018-1305-3
[6] ABHITA MALAVIYA Paul W S. Synergistic Antiproliferative Effects of Combined γ -Tocotrienol and PPAR γ Antagonist Treatment Are Mediated through PPAR γ -Independent Mechanisms in Breast Cancer Cells.[J]. PPAR Research, 2014: 439146. DOI: 10.1155/2014/439146 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
amyjet
|
| Tel: |
4006800868;027-59626688 18371453821;18771149750 |
| Website: |
http://www.amyjet.com/ |
|